SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending due to a significant drop, driven by the expiration of a lock-up period, making a large number of shares available for sale; the community is debating whether this presents a buying opportunity or signals deeper issues, with some pointing to potential insider selling and comparing it to other struggling fintech companies. The high trading volume and price volatility are fueling discussions about potential manipulation and future prospects.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to a recent $75 million investment, fueling speculation about the investor and its implications for the company's growth in AI connectivity. The community is focused on POET's potential in chip-to-chip communication and its role in addressing bottlenecks within AI data centers, viewing it as a key player in the broader AI hardware ecosystem.

American Rebel Holdings, Inc. engages in the design and marketing of branded safes, and personal security and self-defense products. It also designs and manufactures branded apparel and accessories. The company was founded on December 15, 2014 and is headquartered in Brentwood, TN.

American Rebel Holdings Inc

AREB is trending due to a proposed reverse stock split with a unique "round lot protection" clause, sparking mixed reactions; some see it as a buying opportunity, while others fear dilution. Community discussions revolve around the mechanics of the split, its potential impact on share value, and whether it's a strategic move or a sign of underlying issues. Speculation about short squeezes and potential for gains/losses is rampant amid the volatility.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SOUN is trending as investors discuss its potential for a short squeeze, driven by high short interest and recent positive news around AI adoption in the insurance sector. Community members are actively debating entry and exit points, with many expressing bullish sentiment and anticipating a move towards higher price targets. The stock's technicals and potential for disruption in the voice AI space are also fueling the conversation.

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

AlphaTON Capital Corp.

AlphaTON Capital Corp. is trending as community members discuss recent price volatility and potential short squeezes after news of the company's tokenization plans and a closed financing round. Traders are actively debating the stock's momentum, with some pointing to the company's low float and crypto-related initiatives, while others warn of potential pump-and-dump schemes. The conversation includes speculation about upcoming catalysts and potential for both significant gains and losses.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is trending after announcing a commercial agreement with Verizon for satellite-to-phone service by 2026, building on their existing partnership and sparking considerable excitement. The community is buzzing about the potential for seamless nationwide coverage and the stock's impressive gains, while also debating the impact of a recent stock offering and analyst ratings. Many express long-term bullish sentiment, viewing ASTS as a visionary play in the evolving space-based cellular connectivity sector.

Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

Xenetic Biosciences Inc

XBIO is trending as traders discuss the potential for another short squeeze, drawing comparisons to other recent high-flying low float biotech stocks. Community members are actively speculating on potential price targets and entry points, while also noting the company's expanded R&D collaboration with The Scripps Research Institute. Some caution against FOMO (fear of missing out) and highlight the stock's volatility.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending due to community discussion around its potential for a short squeeze, noting high short interest and unusual options activity. Some view it as a leading AI biotech play with significant upside, while others cite concerns about cash burn and insider selling. Optimism remains around potential catalysts, partnerships, and upcoming clinical data.

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

TransCode Therapeutics Inc

RNAZ is trending due to its recent acquisition of Polynoma and a secured $25 million financing, viewed as a significant catalyst despite potential dilution concerns. Community discussions revolve around the company's low float and potential for a squeeze, with some highlighting its cancer treatment advancements. The stock's volatility and upcoming Phase 2 trial are also key talking points.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

DELL is trending due to a mix of analyst upgrades and strong AI server demand, though some express concern over profit margins. Community members are actively discussing whether the stock's price movement reflects its potential, especially given its relatively low valuation compared to other AI-related stocks, as well as discussing the company's new $20 Billion AI server shipment target for FY26.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

iSpecimen Director Resigns Amid Key Shareholder Decisions

iSpecimen (ISPC) has provided an announcement. iSpecimen Inc. announced that director Andrew L. Ross will resign from his position on July 25, 2024...

Comparing iSpecimen (NASDAQ:ISPC) and OneMedNet (NASDAQ:ONMD)

OneMedNet (NASDAQ:ONMD  Get Free Report) and iSpecimen (NASDAQ:ISPC  Get Free Report) are both small-cap computer and technology companies, but which is the better business? We will...

Q4 2023 iSpecimen Inc Earnings Call Transcript

iSpecimen GAAP EPS of -$1.23, revenue of $1.7M

iSpecimen GAAP EPS of -$1.23, revenue of $1.7M...

iSpecimen reports 2023 EPS ($1.23) vs. ($1.16) last year

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

iSpecimen Reports Full Year 2023 Results

LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) ( iSpecimen or the Company ), an online global marketplace that connects scientists requiring biospecimens for...

iSpecimen: Q4 Earnings Insights

iSpecimen Reschedules Full Year 2023 Earnings Release and Conference Call

The Company will now report results after the market closes on March 13, 2024 and reschedules conference call to Thursday, March 14, 2024 at 8:30am EasternLEXINGTON, Mass., March 12, 2024 (GLOBE...

Craig-Hallum Releases a Buy Rating on iSpecimen (ISPC)

Craig-Hallum analyst Matt Hewitt assigned a Buy rating to the stock today. The company's shares closed yesterday at $0.44. According to TipRanks, H...

iSpecimen to Report Full Year 2023 Financial Results on March 13, 2024

LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) ( iSpecimen or the Company ), an online global marketplace that connects scientists requiring biospecimens for...

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in 2009 and is headquartered in Woburn, MA.

iSpecimen Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$1.00
Prev Close	$0.9665
Open	$0.94
Dividend Yield	0.00%
50-Day Moving Average	$1.22
Beta	0.55
Avg. Volume	19.29M
PE Ratio	-0.10

52-Week High	$8.30
52-Week Low	$0.64
Market Capitalization	$7.94M
EPS (Annual)	-$17.58
Price to Book	3.88
Revenue Per Employee	$387,129.79
Enterprise Value/EBITDA	N/A

ISPC iSpecimen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ISPC News